Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
SAN DIEGO, Oct. 24, 2017 -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report third quarter 2017 financial results on Tuesday, November 7, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
Conference Call Information
| Date: | Tuesday, November 7, 2017 |
| Time: | 4:30 p.m. ET |
| Dial-in numbers: | +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International) |
| Confirmation code: | 3889648 |
| Live webcast: | Retrophin.com in the "Events & Presentations" section of the "Investors" page |
A replay of the call will be available from 7:30 p.m. ET, November 7, 2017 to 7:30 p.m. ET, November 14, 2017. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 3889648.
About Retrophin
Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare diseases. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research exploring additional rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam® and Thiola®.
Contact:
Chris Cline, CFA
Vice President, Investor Relations & Corporate Communications
646-564-3680
[email protected]
